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Background/aim: We aimed to compare the effectiveness of esmolol 1 mg/kg and lidocaine 1 mg/kg for injection pain and for the
prevention of rocuronium-induced withdrawal response.
Materials and methods: We enrolled a total of 81 patients in the study. Patients were randomly assigned to receive either 10 mL of
0.9% NaCl (Group P), esmolol 1 mg/kg (Group E), or lidocaine 1.0 mg/kg (Group L). A subparalyzing dose of rocuronium 0.05 mg/
kg was administered to all patients and its effects were recorded. Anesthesia was induced with intravenous propofol and intravenous
rocuronium 0.5 mg/kg in all groups. The withdrawal movements of the patient groups were subsequently graded.
Results: There was a statistically significant difference in overall incidence of pain in group E and L compared to the placebo group
after administrating the subparalyzed dose (no pain response: Group E = 81.5%, Group L = 77.8%, Group P = 14.8%) (P < 0.001). After
intravenous administration of an intubating dose of rocuronium, the esmolol group had a significantly lower incidence of withdrawal
movement than the other groups (no response: Group E = 81.5%, Group L = 63%, Group P = 22.2%) (P < 0.001).
Conclusion: We found that esmolol significantly attenuates rocuronium-induced withdrawal movement and also reduces pain when
used at subparalyzing doses.
Key words: Esmolol, rocuronium, lidocaine, withdrawal movement, injection pain

1. Introduction
Rocuronium is an aminosteroidal nondepolarizing
neuromuscular blocking agent with a rapid onset and
intermediate duration of action (1). Approximately 50%–80%
of rocuronium injections are associated with a withdrawal
response during anesthetic induction (2). Furthermore,
rocuronium may lead to generalized spontaneous
movements, which may increase the risk of reflux of gastric
contents and pulmonary aspiration (2). Moreover, several
publications have reported severe and distressing symptoms
of burning pain following rocuronium injection (3).
Several studies have shown that pretreatment with
lidocaine, fentanyl, ondansetron, magnesium sulfate,
ketamine, and sodium bicarbonate mixture reduced
rocuronium-induced pain (2,4).
Peripheral veins are innerved by polymodal nociceptors
(5). Although the mechanism by which rocuronium
causes injection pain remains unclear, the activation of
C-nociceptors on veins or the triggering of a local quinine
* Correspondence: fatmakavak@yahoo.com

cascade by kininogen release are among the most probable
causes (6).
Owing to its antiinflammatory effects, lidocaine is
used as an adjuvant in multimodal analgesia techniques.
Additionally, it inhibits G protein and NMDA-related
receptors. Furthermore, systemic lidocaine has been
shown to depress spike activities as well as the amplitude
and conduction time of both myelinated A-delta and
unmyelinated C fibers. While lidocaine is usually regarded
as a safe agent, its dose-related side effects on the central
nervous system limit its use in anesthesia (7,8).
Esmolol is a cardioselective β1 adrenergic receptor
antagonist. Intraoperative esmolol infusion has frequently
been used both as an adjuvant to decrease perioperative
opioid consumption and to facilitate fast-track recovery
(9,10). In addition, esmolol activates G proteins on the cell
membrane and causes a central analgesic effect. Several
studies have reported postoperative pain relief following
perioperative esmolol use (11).
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In the current study, we aimed to compare the
effectiveness of esmolol 1 mg/kg and lidocaine 1 mg/kg
on injection pain and on the prevention of rocuroniuminduced withdrawal response.
2. Materials and methods
The study was conducted at the Dışkapı Research and
Training Hospital between January and March 2013.
It was approved by a local research ethics committee
(14 December 2012, No. 12) and was registered in ESM
0538 NCT01824758. After obtaining written informed
consent from all the patients, we enrolled 81 patients of
ASA physical status I–II aged 18–72 years. The patients
were scheduled to undergo elective surgery under
general anesthesia. Our exclusion criteria included the
following: ASA physical status of III or higher, diagnosis
with diabetes, BMI of >40, chronic use of beta-adrenergic
receptor antagonists, pregnancy, and history of hepatic,
renal, or cardiac disease.
We inserted a 20-gauge cannula into the dorsum of
the hand and infused 0.9% sodium chloride to the patient.
The calculated drug doses were adjusted to a volume
of 10 mL with saline solution in Groups P and L (see
explanation of groups below). Patients were monitored
with standard monitors and the solutions were kept at
ambient temperature (20–24 °C).

Patients were randomly assigned to receive 10 mL
of 0.9% NaCl in the placebo group (Group P), esmolol
1 mg/kg in the esmolol group (Brevibloc Premixed
injection, 10 mg/mL, ready-to-use bags, Baxter Healthcare
Corporation, USA) (Group E), or lidocaine 1.0 mg/kg in
the lidocaine group (Jetmonal 2% Ampul, 100 mg/5 mL,
Adeka, Turkey) (Group L) by using computer-generated
random numbers.
Thirty seconds after the administration of the study
drug, a subparalyzing dose of 0.05 mg/kg rocuronium
(Esmeron, intravenous, 50 mg/5 mL, Merck Sharp Dohme,
N.V. Organon, the Netherlands) at room temperature was
diluted in 5 mL of normal saline and injected to all the
patients within 10 s. After counting another 10 s, a blinded
investigator asked the patient if he or she felt any pain in the
arm and documented the patient’s reactions, if any, such as
discomfort, pain, and tears (Table 1). Finally, patients were
induced with propofol 2 mg/kg i.v. and rocuronium 0.5
mg/kg i.v. for 10 s. Following the abolition of the eyelash
reflex, an investigator blinded to the patient grouping
(single-blinded) graded the withdrawal movement as
follows: 0 = no response, 1 = movement/withdrawal at the
wrist only, 2 = movement/withdrawal involving the arm
only (elbow/shoulder), and 3 = generalized response with
movement/withdrawal in more than one extremity, cough,
or breath-holding (11) (Table 2).

Table 1. Pain assessment during an injection of a subparalyzing dose of rocuronium.
Degree of pain

Response

None (0)

Negative response to questioning

Mild (1)

Pain reported in response to questioning only, without any behavioral signs

Moderate (2)

Pain reported in response to questioning and accompanied by a behavioral sign, or pain reported spontaneously
without questioning

Severe (3)

Strong vocal response or response accompanied by facial grimacing, arm withdrawal, or tears

Table 2. Patient assessment of pain during injection of rocuronium.
Pain score

Severity of pain

Patient’s response when questioned regarding pain/discomfort

0

None

No pain or discomfort

1

Mild

Mild pain or discomfort

2

Moderate

Moderate pain or discomfort

3

Severe

Pain or discomfort reported spontaneously and described as becoming severe

4

Very severe

Pain or discomfort reported to be very severe and associated with a strong vocal
response, hand or arm withdrawal, facial grimacing, or crying
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3. Results
Eighty-one patients were enrolled in the study. There was
no significant difference between the demographic data
and ASA status among groups (P = 0.05) (Table 3). There
was a statistically significant difference in overall incidence
of pain and degree of pain in groups E and L compared to
the placebo group after administrating the subparalyzing
dose (P < 0.001) (Table 4). However, the incidence and
degree of pain was similar between groups E and L after
administrating the subparalyzing dose (P = 0.735) (Table 4).
The incidence of “no response” withdrawal movement
following intravenous administration of the intubating
dose of rocuronium was 81.5%, 63%, and 22.2% in the
esmolol, lidocaine, and placebo groups, respectively (P <
0.001). Generalized movement was not seen in any of the
groups (Table 5). We did not observe erythema or venous
sequelae in any of the patients during the 24-h follow-up,
and no patients reported pain or discomfort.

Following muscular relaxation, tracheal intubation was
performed and ETCO2 was maintained between 32 and 42
mmHg with a fresh gas flow rate of 4 L/min. Anesthesia
was maintained with 50% nitrous oxide in oxygen and
sevoflurane to maintain blood pressure and heart rate
within 20% of baseline values. We assessed the patients’
hands for erythema, thrombophlebitis, and thrombosis,
both after injection and 24 h postoperatively.
Sample size estimation was performed using NCSS and
PASS 2000 (NCSS LLC, USA) software. We performed a
power analysis estimating a frequency of 80% of patients
who would experience rocuronium-induced pain or
withdrawal movement and found that we required a
minimum of 27 patients in each group to detect a 50%
reduction at a significance level of 5% and a probability
(power) of 80%.
We used SPSS 16.0 for Windows (SPSS Inc., USA) to
perform data analysis. While continuous variables were
expressed as mean ± standard deviation, categorical data
were expressed as n (%). The mean difference in age and
weight among groups was compared with the Kruskal–
Wallis test. Categorical data were analyzed by Pearson’s
chi-square test. P < 0.05 was considered statistically
significant.

4. Discussion
In the current study, we demonstrated that esmolol
significantly reduces withdrawal movement related to the
administration of an intubating dose of rocuronium as
compared with placebo and lidocaine groups. Additionally,

Table 3. Demographic data.
Group E
(n = 27)

Group L
(n = 27)

Group P
(n = 27)

P-value

Age, years*

50 (36–58)

44 (36–52)

47 (34–57)

0.6

Sex, M/F

7/20

5/22

7/20

0.7

Weight, kg

75.88 ± 14.65

81.18 ± 16.14

81.11 ± 12.21

0.3

Height, cm

163.88 ± 6.5

159.92 ± 8.19

162.25 ± 6.75

0.1

ASA physical status, I/II

10/17

14/13

13/14

0.5

*: Median (interquartile range).
Table 4. Severity of pain during the injection of a subparalyzing dose of rocuronium.
Degree of pain

Esmolol group
(n = 27)

Lidocaine group
(n = 27)

Placebo group
(n = 27)

P-value

No pain (0)

22 (81.5%)

21 (77.8%)

4 (14.8%)

P < 0.001

Mild pain (1)

4 (14.8%)

6 (22.2%)

12 (44.4%)

P = 0.039

Moderate pain (2)

1 (3.7%)

0 (0.0%)

5 (18.5%)

P < 0.001

Severe pain (3)

0 (0.0%)

0 (0.0%)

6 (22.2%)

P < 0.001

Yes pain

5 (18.5%) #

6 (22.2%) #

23 (85.2%)

P < 0.01

#: P = 0.735 vs. lidocaine group.
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Table 5. Withdrawal reactions associated with the intravenous administration of an intubating dose of
rocuronium.
Degree of withdrawal
reactions

Esmolol group
(n = 27)

Lidocaine group
(n = 27)

Placebo group
(n = 27)

P-value

No response (1)

22 (81.5%)

17 (63.0%)

6 (22.2%)

P < 0.001

Wrist (2)

4 (14.8%)

9 (33.3%)

11 (40.7%)

P = 0.09

Elbow/shoulder (3)

1 (3.7%)

1 (3.7%)

10 (37.0%)

P < 0.001

Generalized response (4) 0 (0.0%)

0 (0.0%)

0 (0.0%)

-

Yes response (total)

10 (37.0%) #

21 (77.8%)

P < 0.05

5 (18.5%) #

Values are presented as numbers (percentages).
#: P < 0.05 vs. lidocaine group.

esmolol equally attenuated pain and withdrawal
movement as did lidocaine following the administration
of a subparalyzing dose of rocuronium.
Although rocuronium is regarded as an ideal
nondepolarizing neuromuscular blocker owing to its
fast onset of action (12), 50%–80% of patients report
rocuronium-induced burning pain (13). Peripheral
veins are innervated by polymodal nociceptors, which
are thought to mediate the injection response of certain
anesthetics. Blunk et al. (8) demonstrated that the direct
activation of C-nociceptors could be mediating the burning
sensation caused by aminosteroidal neuromuscular
blocking drugs. Lidocaine, which is an amide derivative
with analgesic, anesthetic, and antiinflammatory effects,
is known to be the most effective agent in relieving
rocuronium-induced pain. This presumed analgesic effect
is thought to be related to sodium channel blockage, G
protein-related receptor inhibition, and NMDA receptor
inhibition (9).
Mencke et al. reported a 33% incidence of pain in
patients who received a precurarization (0.03 mg/kg in
5 mL of saline) dose of rocuronium (14). Yavascaoglu et
al. (5) reported a 63% incidence of pain in patients who
received a higher subparalyzing dose of rocuronium (0.05
mg/kg in 5 mL of saline) following 0.5 mg/kg esmolol and
0.5 mg/kg lidocaine. In the current study, 85% of patients
who received a rocuronium dose of 0.05 mg/kg in 5 mL
of saline experienced injection pain, and a similar rate of
patients in groups E and L reported attenuation of pain.
The fact that patients in groups E and L achieved a higher
rate of analgesic effect may be explained by our use of a
higher dosage of esmolol (1 mg/kg) and lidocaine (1 mg/
kg) compared to Yavascaoglu et al.
Rocuronium-induced withdrawal movements may
primarily cause displacement of the venous catheter and
may lead to pulmonary aspiration of gastric contents. They
may even induce bronchospasm, asthma, or myocardial
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infarction (15,16). Several drugs, such as lidocaine,
tramadol, fentanyl, ondansetron, remifentanil, and a
mixture of sodium bicarbonate and rocuronium, have
been previously assessed for their potential to reduce
rocuronium-induced injection pain (13,17–19).
Cheong and Wong compared the use of 10 mg and 30
mg of lidocaine pretreatment in adult patients and found
that although 30 mg was more effective, both significantly
reduced the incidence and severity of rocuronium-induced
pain (20). Yavascaoglu et al. similarly demonstrated
that i.v. lidocaine administration significantly reduced
the rate of patients experiencing rocuronium-induced
injection pain as compared with the placebo (5). The use
of lidocaine, however, is associated with several side effects
such as coughing, chest rigidity, hypotension, bradycardia,
and anaphylaxis (15). Salman et al. compared the analgesic
effects of esmolol 10 mg and lidocaine 40 mg following
propofol infusion and found that, although the dose was
lower, esmolol provided better analgesia than lidocaine
(21).
Esmolol is an ultrashort-acting, cardioselective beta-1
receptor antagonist. It is a moderate lipophilic drug and
takes part in central adrenergic activation. Additionally,
it is effective in blunting adrenergic responses related
to several perioperative stimuli such as the application
of a laryngoscope, intraoperative events, and tracheal
extubation (10). Esmolol-associated postoperative
analgesia has been attributed to several mechanisms.
Functional MRI studies have demonstrated hippocampal
activation following anxiety, emotional stress, and fear. The
hippocampus is estimated to participate in nociception
induced by at least some of the NMDA receptors, and
the activation of hippocampal beta adrenergic receptors
is thought to influence nociception. By blocking these
receptors, we may attenuate nociceptive processing and
relieve pain (22).
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A limitation of this study is the lack of pH and osmolality
analysis of solutions (saline, esmolol/saline, and lidocaine).
Further studies performing these analyses on all patients
may help elucidate the cause of injection pain.
In the current study, we observed that withdrawal
movements and hemodynamic effects were significantly

attenuated by esmolol 1 mg/kg. Although esmolol may
cause hypotension and bradycardia, we did not observe any
side effect or negative hemodynamic signs associated with
its use. In conclusion, we found that esmolol significantly
attenuates rocuronium-induced withdrawal movement
and also reduces pain when used at subparalyzing doses.
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